Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
clinical trials
fda
indiana blog main
indiana top stories
life sciences
national blog main
raleigh-durham blog main
5
×
raleigh-durham top stories
amgen
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
migraine research foundation
national
teva pharmaceutical
allergan
calcitonin gene-related peptide
chronic migraine
eptinezumab
erenumab
fremanezumab
galcanezumab
What
fda
5
×
won
approval
drug
migraine
new
class
decades
developed
drugs
friday
oral
acute
addresses
agency
aimmune
allergy
amgen
approved
arguments
august
awarded
big
bio
biotech
busy
candidates
causes
commercialized
companies
competitors
condition
days
decisions
devices
eli
gets
giant
giving
head
Language
unset
Current search:
won���t
×
fda
×
" raleigh-durham blog main "
×
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines